Valganciclovir

Evidence Level: L4

Predicted Indications: 10

Valganciclovir
Valganciclovir: From Cytomegalovirus Infection to Rheumatoid Arthritis

## Pharmacist Assessment Report

Valganciclovir: From Cytomegalovirus Infection to Rheumatoid Arthritis

One-Sentence Summary

Valganciclovir is an oral antiviral prodrug of ganciclovir, used against cytomegalovirus (CMV) infection. The TxGNN model predicts it may be effective for rheumatoid arthritis, but no clinical trials are registered. The 14 publications retrieved are mostly case reports and reviews of CMV complications in RA patients on immunosuppressants, so they do not show efficacy against RA itself.

Quick Overview

Item	Content
Original Indication	Not stated in the Singapore licence records. Known use: CMV infection (retinitis, transplant prophylaxis)
Predicted New Indication	Rheumatoid arthritis
TxGNN Prediction Score	98.97%
Evidence Level	L4
Singapore Market Status	✓ Marketed
Number of Registrations	2
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Valganciclovir is known to be a prodrug of ganciclovir, which inhibits CMV DNA polymerase. Its efficacy in CMV disease is established, but a direct mechanistic route to rheumatoid arthritis is not evident.

The literature links the two conditions only indirectly. RA patients on immunosuppressants, including methotrexate, anti-TNF agents and JAK inhibitors such as tofacitinib and upadacitinib, can develop opportunistic CMV disease (ileocolitis, gastritis, retinitis). Valganciclovir treats those infections. It is not shown to change RA disease activity.

One 2026 preclinical study (in silico, in vitro and in vivo) preliminarily evaluated valganciclovir hydrochloride as a possible modulator of IL-6 receptor signalling. This is the only item pointing to a possible anti-RA mechanism, and it is early-stage work.

The high TxGNN score most likely reflects the co-occurrence of CMV and RA in the literature. It should not be read as evidence of efficacy.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The retrieved literature contains no RCTs. Priority is given to the preclinical repurposing study, then reviews, then case reports.

PMID	Year	Type	Journal	Key Findings
42820990	2026	Preclinical (in silico/in vitro/in vivo)	Naunyn-Schmiedeberg's Arch Pharmacol	Valganciclovir hydrochloride preliminarily evaluated as a modulator of IL-6 receptor signalling in RA
41792858	2026	Review	Int J Retina Vitreous	Six reported cases of CMV retinitis associated with JAK inhibitors
18068874	2008	Review	La Revue de Médecine Interne	No guidelines exist on antiviral use for symptomatic CMV in patients on immunosuppressants for chronic inflammatory disease
15155152	2004	Review	Expert Opin Drug Saf	Drugs associated with retinal toxicity
26150269	2015	Case report and review	Reumatismo	CMV ileocolitis in an RA patient on immunosuppressive therapy
41779881	2025	Case report	Retinal Cases Brief Rep	Two RA patients developed CMV retinitis on tofacitinib
41526852	2026	Case report	BMC Ophthalmol	CMV retinitis with retinal ischaemia and vitreous haemorrhage on upadacitinib
28389165	2017	Case report	J Infect Chemother	CMV retinitis followed by immune recovery uveitis in an elderly RA patient on methotrexate plus tofacitinib
15494900	2004	Case report	Clin Infect Dis	CMV retinitis in an RA patient on anti-TNF-α therapy
25697299	2015	Case report	BMJ Case Rep	Frail elderly man with seronegative RA, bowel perforation and CMV disease

Singapore Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
SIN15779P	VALGAN 450 Valganciclovir Film-Coated Tablet 450 mg	Film-coated tablet	Not listed in the data
SIN12393P	VALCYTE Tablet 450 mg	Film-coated tablet	Not listed in the data

Safety Considerations

Drug Interactions: The interaction screen returned 100 records. The main entries listed are:

Moderate: amphotericin B (including lipid complex, cholesteryl sulfate and liposomal forms) and trospium
Unknown severity: calcitriol, pantoprazole, omeprazole, lansoprazole, clotrimazole, morphine, metformin, vancomycin, nizatidine, oxandrolone, prednisone, hydrocortisone, simvastatin, mannitol, dolasetron

Concomitant use with immunosuppressants and other myelosuppressive or nephrotoxic agents needs particular attention in RA patients. Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale:

The prediction rests on model output and indirect literature only. The papers describe valganciclovir treating CMV complications in RA patients, not RA itself.
No clinical trials are registered, and the only mechanistic signal (IL-6 receptor modulation) is a single early preclinical study.

To proceed, the following is needed:

Mechanism of action data, and independent confirmation of the IL-6 signalling finding
Controlled studies showing an effect on RA disease activity, distinct from CMV prevention or treatment
Package insert warnings and contraindications, and the approved indication text for the Singapore licences
A benefit-risk assessment of long-term use in RA, given the myelosuppression and nephrotoxicity profile of the drug class and the interactions with immunosuppressants

Other predicted indications: None of the other nine candidates changes this assessment.

Bronchitis: the supporting cohort studies are about CMV prophylaxis in lung transplant recipients and cannot be extrapolated.
Headache disorder: the literature covers herpesvirus encephalitis, with no evidence in primary headache.
Laryngotracheitis, trigeminal autonomic cephalalgia, tendinitis, osteoarthritis susceptibility and three rare genetic syndromes: no literature, no trials, and no plausible mechanism.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.